Assuntos
Humanos , Masculino , Íleo , Pólipos Intestinais/diagnóstico , Pólipos Intestinais , Síndrome de Peutz-Jeghers/complicações , Síndrome de Peutz-Jeghers/diagnóstico , Síndrome de Peutz-Jeghers/epidemiologia , Síndrome de Peutz-Jeghers/etiologia , Síndrome de Peutz-Jeghers/fisiopatologia , Síndrome de Peutz-Jeghers/genética , Síndrome de Peutz-Jeghers/patologia , Adolescente , Enteropatias , Tomografia Computadorizada por Raios XAssuntos
Humanos , Masculino , Íleo , Pólipos Intestinais/diagnóstico , Pólipos Intestinais/diagnóstico por imagem , Síndrome de Peutz-Jeghers/complicações , Síndrome de Peutz-Jeghers/diagnóstico , Síndrome de Peutz-Jeghers/epidemiologia , Síndrome de Peutz-Jeghers/etiologia , Síndrome de Peutz-Jeghers/genética , Síndrome de Peutz-Jeghers/patologia , Síndrome de Peutz-Jeghers/fisiopatologia , Enteropatias/diagnóstico , Enteropatias/etiologia , Enteropatias/terapia , AdolescenteRESUMO
Bromperidol therapeutic efficacy, and tolerance was studied by means of a 3-month open trial on 25 chronic psychotic female inpatients from a room at San Juan ward for medium to extensive length of stay, The Braulio A. Moyano National Psychiatric Hospital, Buenos Aires. This drug was administered orally on a single 10- to 35 mg night dose. No effect whatsoever was observed on periodic catatonia. However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution.
Assuntos
Haloperidol/análogos & derivados , Transtornos Psicóticos/tratamento farmacológico , Adolescente , Adulto , Idoso , Doença Crônica , Ensaios Clínicos como Assunto , Feminino , Haloperidol/administração & dosagem , Haloperidol/efeitos adversos , Haloperidol/uso terapêutico , Humanos , Pacientes Internados , Pessoa de Meia-Idade , Transtornos Paranoides/tratamento farmacológico , Esquizofrenia/tratamento farmacológicoRESUMO
Bromperidol therapeutic efficacy, and tolerance was studied by means of a 3-month open trial on 25 chronic psychotic female inpatients from a room at San Juan ward for medium to extensive length of stay, The Braulio A. Moyano National Psychiatric Hospital, Buenos Aires. This drug was administered orally on a single 10- to 35 mg night dose. No effect whatsoever was observed on periodic catatonia. However, its being well-tolerated and effective on chronic psychotic patients, coupled to the [quot ]bonus[quot ] of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution.
RESUMO
The author makes both a historical and up-to-date review of the "schizophrenic defect" concept (S.D.). He comes to the conclusion that this is the "morbid residual" or balance left as "ideo-affective" capital after every productive psychotic outbreak. The S.D. is studied in a "Medium and Long Term" Ward with prevailing statistics amounting to 33% D.E. patients plus 9% active schizophrenic patients over a total average of 100 chronic hospitalized patients. It was found out that 33% of that universe had some scattered family whereas 19% of these patients had no family at all. The latter showed strong tendency towards isolation, slovenliness and "hospitalism". They became "passive-dependent" patients. The situational framework is analyzed. Medical staff relation ships with patients, type of treatment and the illusion created by "fictitious discharge" of E.D. under no favorable psycho-environmental conditions are taken into account. Methods to improve the situation are then outlined and discussed. The following topics are considered: correct therapeutics, family therapy, sectorization, therapeutic community, transition homes (foyers), and current legislation.
Assuntos
Esquizofrenia/história , Terapia Familiar , História do Século XVIII , História do Século XIX , História do Século XX , História Medieval , Hospitais Psiquiátricos , Humanos , Psicoterapia , Esquizofrenia/etiologia , Esquizofrenia/terapia , Comunidade TerapêuticaRESUMO
The author makes both a historical and up-to-date review of the [quot ]schizophrenic defect[quot ] concept (S.D.). He comes to the conclusion that this is the [quot ]morbid residual[quot ] or balance left as [quot ]ideo-affective[quot ] capital after every productive psychotic outbreak. The S.D. is studied in a [quot ]Medium and Long Term[quot ] Ward with prevailing statistics amounting to 33
D.E. patients plus 9
active schizophrenic patients over a total average of 100 chronic hospitalized patients. It was found out that 33
of that universe had some scattered family whereas 19
of these patients had no family at all. The latter showed strong tendency towards isolation, slovenliness and [quot ]hospitalism[quot ]. They became [quot ]passive-dependent[quot ] patients. The situational framework is analyzed. Medical staff relation ships with patients, type of treatment and the illusion created by [quot ]fictitious discharge[quot ] of E.D. under no favorable psycho-environmental conditions are taken into account. Methods to improve the situation are then outlined and discussed. The following topics are considered: correct therapeutics, family therapy, sectorization, therapeutic community, transition homes (foyers), and current legislation.
